Chinese Academy of Sciences, the famous Wu Meng-chao Hepatobiliary surgeon at the national Pharmaceutical Biotechnology Association recently held China Precision Medical Branch, said the National Center for Science liver cancer is expected in October this year in Anting Town, Jiading District, Shanghai appearances, and the Second Military Medical University, Eastern Hepatobiliary surgical Hospital during the year will also be the overall move to Anting, number of beds from the original more than 700 sheets expandable to 1500.

At the same time, Eastern Hepatobiliary Surgery Hospital Anting district hospital of liver cancer science research center will be established by the academician Wu 孟超等 six co-founded, and the hospital will be set up at a hundred meters apart Shanghai Engineering Research Center for treatment of cells, to develop research immunotherapy.

According to previous news, "National HCC Science Center" by the National Development and Reform Commission approval, Second Military Medical University Joint Fudan University, Shanghai Jiaotong University jointly set up the declaration.April 1, 2012 in the morning to start the construction in the west of the Eastern Hepatobiliary Surgery Hospital, the new hospital district Anting Town, Jiading District, Shanghai, is following the National Center for Nanoscience examination and approval by the National Development and Reform Commission's second national science centers, the total investment of 150 billion yuan. The Centre will focus on significantly reduce the incidence of liver cancer, mortality targets, focusing liver cancer research in the field of major scientific and technological key issues, to carry out basic and applied basic research of liver cancer.

Research priorities include: hepatitis - cirrhosis of early warning and prevention research to the development of liver cancer, liver cancer marker screening and applications, the development of the molecular mechanism of liver cancer early diagnosis, molecular typing and individualized therapy, drug target identification and targeting intervention studies, systemic regulation of the molecular mechanism of liver cancer recurrence and metastasis and intervention techniques, the host and the micro-environment, explore new ways of liver cancer biotherapy, comprehensive treatment of liver cancer and evaluation and optimization of new therapeutic programs.

The center consists of a diagnostic marker for screening and molecular typing laboratory, the pathogen, host interaction analytical laboratory, molecular networks regulated research, drug target discovery and R & D labs, cell therapy research, evidence-based medicine Laboratory 6 core platform as well as resource preservation and data link application center, animal center, pilot platform three public assistance constitutes R & D platform.